Does treat to target or achieving remission improve radiographic outcome in psa?

Does treat to target or achieving remission improve radiographic outcome in psa?

Bibliográfalaš dieđut
Váldodahkkit:	Coates, L, Hensor, E, Emery, P, Conaghan, P, Helliwell, P
Materiálatiipa:	Conference item
Almmustuhtton:	Wiley 2016

Geahča maid

What should be the primary target of ‘treat to target’ in PsA?
Dahkki: Coates, L, et al.
Almmustuhtton: (2018)

What should be the primary target of "treat to target" in psoriatic arthritis?
Dahkki: Coates, LC, et al.
Almmustuhtton: (2018)

Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment
Dahkki: Coates, LC, et al.
Almmustuhtton: (2021)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
Dahkki: Coates, L, et al.
Almmustuhtton: (2022)

The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.
Dahkki: Coates, L, et al.
Almmustuhtton: (2017)

Treat-to-target in PsA: methods and necessity
Dahkki: Dures, E, et al.
Almmustuhtton: (2020)

Treat-to-target in PsA: methods and necessity
Dahkki: Laura C Coates, et al.
Almmustuhtton: (2020-02-01)

The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes
Dahkki: De Marco, G, et al.
Almmustuhtton: (2017)

High prevalence of radiographic erosions in early, untreated PsA: results from the SpARRO cohort
Dahkki: Richard J Wakefield, et al.
Almmustuhtton: (2024-05-01)

Remission in psoriatic arthritis—where are we now?
Dahkki: Coates, L, et al.
Almmustuhtton: (2017)

How routine use of a treat to target approach in PsA might impact on clinical decision making
Dahkki: Coates, L
Almmustuhtton: (2017)

Value of RAPID3 in patients with PsA: results from the TICOPA and LOPAS II databases
Dahkki: Coates, L, et al.
Almmustuhtton: (2017)

Sustained very low disease activity and remission in psoriatic arthritis patients
Dahkki: Lubrano, E, et al.
Almmustuhtton: (2019)

Frequency of remission achievement in the pre-treat-to-target decade in juvenile idiopathic arthritis
Dahkki: Ana Isabel Rebollo-Giménez, et al.
Almmustuhtton: (2025-01-01)

Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial
Dahkki: Coates, L, et al.
Almmustuhtton: (2019)

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
Dahkki: O'Brien, M, et al.
Almmustuhtton: (2009)

Comparing psoriatic arthritis low-field magnetic resonance imaging, ultrasound and clinical outcomes: data from the TICOPA trial
Dahkki: Helliwell, P, et al.
Almmustuhtton: (2019)

Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PSA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
Dahkki: Coates, LC, et al.
Almmustuhtton: (2022)

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab
Dahkki: Coates, L, et al.
Almmustuhtton: (2018)

Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
Dahkki: Coates, LC, et al.
Almmustuhtton: (2021)

Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
Dahkki: McGagh, D, et al.
Almmustuhtton: (2020)

Low PSA radiographic disease progression on C11‐choline PET
Dahkki: Ahmed M. Mahmoud, et al.
Almmustuhtton: (2024-02-01)

The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes
Dahkki: Gabriele De Marco, et al.
Almmustuhtton: (2017-07-01)

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study
Dahkki: Tore K Kvien, et al.
Almmustuhtton: (2022-01-01)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
Dahkki: Ennio Lubrano, et al.
Almmustuhtton: (2019-08-01)

Considerations for the definition of remission criteria in psoriatic arthritis
Dahkki: Mease, P, et al.
Almmustuhtton: (2017)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
Dahkki: Helliwell, PS, et al.
Almmustuhtton: (2022)

Patient-reported outcomes and radiographic progression in patients with rheumatoid arthritis in sustained remission versus low disease activity
Dahkki: Annette H M van der Helm-van Mil, et al.
Almmustuhtton: (2024-02-01)

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
Dahkki: Coates, LC, et al.
Almmustuhtton: (2023)

Early improvement of painful symptoms in MDD: is there an association in achieving remission?
Dahkki: Bär Karl-Jürgen
Almmustuhtton: (2007-12-01)

Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial
Dahkki: Orbai, AM, et al.
Almmustuhtton: (2021)

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
Dahkki: Philip J Mease, et al.
Almmustuhtton: (2023-04-01)

Ethical issues in a TwiCs study in early PsA
Dahkki: Coates, L, et al.
Almmustuhtton: (2017)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
Dahkki: Nash AI, et al.
Almmustuhtton: (2019-03-01)

Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/ml
Dahkki: Emerson P. Gregorio, et al.
Almmustuhtton: (2007-04-01)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
Dahkki: Atul Deodhar, et al.
Almmustuhtton: (2022-07-01)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
Dahkki: M Verstappen, et al.
Almmustuhtton: (2020-02-01)

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
Dahkki: Coates, L, et al.
Almmustuhtton: (2018)

Efficacy of duloxetine in achieving response and remission
Dahkki: Bauer Michael
Almmustuhtton: (2006-02-01)

Cost-effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of a multicenter randomized controlled trial
Dahkki: O'Dwyer, J, et al.
Almmustuhtton: (2018)